The consistency of the results of three assay methods (RT-PCR, immunoblotting and immunohistochemistry) and the repeat validations in the test as well as the independent validation cohort, provide with essential, reliable evidence for the clinical significance of MACC1 as a prognostic biomarker for HCC. This evidence concerns the gene MACC1 and hepatocellular carcinoma.